Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3795 Target Snapshot

Melanocyte-stimulating hormone receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,390Compounds
304Assays
7Approved Drugs
2,032.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Melanocyte-stimulating hormone receptor shows approved-linked disease relevance led by erythropoietic protoporphyria. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q01726. Start with erythropoietic protoporphyria, then reuse UniProt Q01726 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with erythropoietic protoporphyria, then reuse UniProt Q01726 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
erythropoietic protoporphyria

Melanocyte-stimulating hormone receptor shows approved-linked disease relevance led by erythropoietic protoporphyria. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with erythropoietic protoporphyria because it currently carries approved-linked support. Linked drugs include AFAMELANOTIDE, AFAMELANOTIDE ACETATE, DERSIMELAGON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Melanocyte-stimulating hormone receptor as ChEMBL target CHEMBL3795, mapped to UniProt Q01726. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Melanocyte-stimulating hormone receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3795
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q01726
Melanocyte-stimulating hormone receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Melanocyte-stimulating hormone receptor is the right protein anchor across sources, using UniProt Q01726 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why erythropoietic protoporphyria is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMelanocyte-stimulating hormone receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ01726
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMelanocyte-stimulating hormone receptor
UniProt AccessionQ01726
Component TypeProtein
Sequence Length317 aa

Melanocyte-stimulating hormone receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Melanocyte-stimulating hormone receptor, mapped to UniProt Q01726. Sequence length is 317 aa.

Mapped IDQ01726
Review nameMelanocyte-stimulating hormone receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Melanocyte-stimulating hormone receptor shows approved-linked disease relevance led by erythropoietic protoporphyria. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
erythropoietic protoporphyria
3 linked drugs · 3 direct · 3 efficacy
Linked drugAFAMELANOTIDE
Linked drugAFAMELANOTIDE ACETATE
Linked drugDERSIMELAGON
Clinical signal Phase II
acne
1 linked drug · 1 direct · 1 efficacy
Linked drugAFAMELANOTIDE
Clinical signal Phase II
Acute kidney injury
1 linked drug · 1 direct · 1 efficacy
Linked drugMODIMELANOTIDE
Clinical signal Phase II
aortic aneurysm
1 linked drug · 1 direct · 1 efficacy
Linked drugMODIMELANOTIDE
Clinical signal Phase II
diffuse scleroderma
1 linked drug · 1 direct · 1 efficacy
Linked drugDERSIMELAGON
Clinical signal Phase II
Ischemic stroke
1 linked drug · 1 direct · 1 efficacy
Linked drugAFAMELANOTIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with erythropoietic protoporphyria because it currently carries approved-linked support. Linked drugs include AFAMELANOTIDE, AFAMELANOTIDE ACETATE, DERSIMELAGON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseerythropoietic protoporphyria
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
4
Phase II
Assay Mix

Activity Type Distribution

IC50475.0
KI597.0
EC50956.0
KD4.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3898758 11.0 EC50 0.01 Preclinical
CHEMBL3920516 11.0 Ki 0.01 Preclinical
CHEMBL3928766 11.0 Ki 0.01 Preclinical
CHEMBL3972160 11.0 Ki 0.01 Preclinical
CHEMBL3975096 11.0 Ki 0.01 Preclinical
CHEMBL4093140 11.0 EC50 0.01 Preclinical
CHEMBL4093140 11.0 IC50 0.01 Preclinical
CHEMBL569693 11.0 EC50 0.01 Preclinical
CHEMBL3958741 10.92 EC50 0.012 Preclinical
CHEMBL3964400 10.92 Ki 0.012 Preclinical
Distribution

pChEMBL Value Distribution

115
5.0
191
5.5
271
6.0
197
6.5
162
7.0
132
7.5
137
8.0
127
8.5
104
9.0
73
9.5
pChEMBL
Approved Drugs

Approved Drugs

SETMELANOTIDE
CHEMBL3301624
Approved 2020
Properties Compare Identifier
BREMELANOTIDE
CHEMBL2070241
Approved 2019
Properties Compare Identifier
AFAMELANOTIDE
CHEMBL441738
Approved 2014
Properties Compare Identifier
Assay Landscape

Assay Landscape

304
Total Assays
823
Tested Compounds
2
Assay Types
Functional — 163 assays, 668 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 110 488 7.7
assay format 53 180 7.2
Binding — 141 assays, 823 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 83 532 7.2
single protein format 53 154 6.6
assay format 3 82 6.3
cell membrane format 2 55 8.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine